S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
NASDAQ:FLDM

Fluidigm Stock Forecast, Price & News

$3.13
-0.15 (-4.57%)
(As of 01/14/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.03
$3.29
50-Day Range
$3.13
$4.92
52-Week Range
$3.03
$7.51
Volume
702,259 shs
Average Volume
807,240 shs
Market Capitalization
$239.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.17
30 days | 90 days | 365 days | Advanced Chart
Receive FLDM News and Ratings via Email

Sign-up to receive the latest news and ratings for Fluidigm and its competitors with MarketBeat's FREE daily newsletter.


Fluidigm logo

About Fluidigm

Fluidigm Corp. is engaged in the development, manufacture and marketing of biotechnology tools fro life sciences research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics; and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen R. Quake and Gajus V. Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:FLDM
CUSIP
34385P10
Employees
627
Year Founded
N/A

Sales & Book Value

Annual Sales
$138.14 million
Book Value
$1.88 per share

Profitability

Net Income
$-53.02 million
Pretax Margin
-51.46%

Debt

Price-To-Earnings

Miscellaneous

Free Float
74,268,000
Market Cap
$239.40 million
Optionable
Optionable

Company Calendar

Last Earnings
11/07/2021
Today
1/17/2022
Next Earnings (Estimated)
2/09/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.03 out of 5 stars

Medical Sector

574th out of 1,417 stocks

Analytical Instruments Industry

15th out of 33 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Fluidigm (NASDAQ:FLDM) Frequently Asked Questions

Is Fluidigm a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fluidigm in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Fluidigm stock.
View analyst ratings for Fluidigm
or view top-rated stocks.

How has Fluidigm's stock price been impacted by Coronavirus?

Fluidigm's stock was trading at $2.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FLDM stock has increased by 19.0% and is now trading at $3.13.
View which stocks have been most impacted by COVID-19
.

When is Fluidigm's next earnings date?

Fluidigm is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Fluidigm
.

How were Fluidigm's earnings last quarter?

Fluidigm Co. (NASDAQ:FLDM) issued its quarterly earnings results on Sunday, November, 7th. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.22) by $0.04. The medical research company had revenue of $28.50 million for the quarter. Fluidigm had a negative trailing twelve-month return on equity of 43.70% and a negative net margin of 49.54%. During the same period last year, the firm posted ($0.03) EPS.
View Fluidigm's earnings history
.

What guidance has Fluidigm issued on next quarter's earnings?

Fluidigm issued an update on its FY 2021 earnings guidance on Monday, December, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $123 million-$127 million, compared to the consensus revenue estimate of $137 million.

What price target have analysts set for FLDM?

1 equities research analysts have issued 12-month price objectives for Fluidigm's shares. Their forecasts range from $7.00 to $7.00. On average, they expect Fluidigm's stock price to reach $7.00 in the next year. This suggests a possible upside of 123.6% from the stock's current price.
View analysts' price targets for Fluidigm
or view top-rated stocks among Wall Street analysts.

Who are Fluidigm's key executives?

Fluidigm's management team includes the following people:
  • Stephen Christopher Linthwaite, President, Chief Executive Officer & Director
  • Bradley Kreger, Senior Vice President-Global Operations
  • Vikram Jog, Chief Financial Officer
  • David A. King, Vice President-Research & Development
  • Andrew Quong, Chief Science Officer

What is Chris Linthwaite's approval rating as Fluidigm's CEO?

30 employees have rated Fluidigm CEO Chris Linthwaite on Glassdoor.com. Chris Linthwaite has an approval rating of 78% among Fluidigm's employees.

What other stocks do shareholders of Fluidigm own?

What is Fluidigm's stock symbol?

Fluidigm trades on the NASDAQ under the ticker symbol "FLDM."

How do I buy shares of Fluidigm?

Shares of FLDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fluidigm's stock price today?

One share of FLDM stock can currently be purchased for approximately $3.13.

How much money does Fluidigm make?

Fluidigm has a market capitalization of $239.40 million and generates $138.14 million in revenue each year. The medical research company earns $-53.02 million in net income (profit) each year or ($0.90) on an earnings per share basis.

How many employees does Fluidigm have?

Fluidigm employs 627 workers across the globe.

What is Fluidigm's official website?

The official website for Fluidigm is www.fluidigm.com.

Where are Fluidigm's headquarters?

How can I contact Fluidigm?

Fluidigm's mailing address is 2 Tower Place Ste 2000, South San Francisco CA, 94080. The medical research company can be reached via phone at (650) 266-6000, via email at [email protected], or via fax at 650-871-7152.


This page was last updated on 1/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.